U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Medulloblastoma(MDB)

MedGen UID:
7517
Concept ID:
C0025149
Neoplastic Process
Synonyms: MDB; MEDULLOBLASTOMA PREDISPOSITION SYNDROME; Medulloblastoma, somatic; Medulloblastoma, SUFU-Related
SNOMED CT: Medulloblastoma (443333004); Medulloblastoma (1156923005); MDB - medulloblastoma (1156923005)
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
Concept ID:
CN307044
Finding
Source: Orphanet
clinical entity without genetic inheritance.
 
Genes (locations): BRCA2 (13q13.1); CTNNB1 (3p22.1); ELP1 (9q31.3); GPR161 (1q24.2); PTCH2 (1p34.1); SUFU (10q24.32)
 
HPO: HP:0002885
Monarch Initiative: MONDO:0007959
OMIM®: 155255
Orphanet: ORPHA616

Definition

Medulloblastoma is the most common brain tumor in children. It accounts for 16% of all pediatric brain tumors, and 40% of all cerebellar tumors in childhood are medulloblastoma. Medulloblastoma occurs bimodally, with peak incidences between 3 and 4 years and 8 and 9 years of age. Approximately 10 to 15% of medulloblastomas are diagnosed in infancy. Medulloblastoma accounts for less than 1% of central nervous system (CNS) tumors in adults, with highest incidence in adults 20 to 34 years of age. In 1 to 2% of patients, medulloblastoma is associated with Gorlin syndrome (109400), a nevoid basal carcinoma syndrome. Medulloblastoma also occurs in up to 40% of patients with Turcot syndrome (see 276300). Medulloblastoma is thought to arise from neural stem cell precursors in the granular cell layer of the cerebellum. Standard treatment includes surgery, chemotherapy, and, depending on the age of the patient, radiation therapy (Crawford et al., 2007). Millard and De Braganca (2016) reviewed the histopathologic variants and molecular subgroups of medulloblastoma. Pretreatment prognosis of medulloblastoma has been refined by histopathologic subclassification into the following variants: large-cell medulloblastoma, anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity (MBEN). The latter 2 groups have been shown to have a significantly superior prognosis as compared to the large cell and anaplastic groups in young children. At the molecular level, medulloblastomas have been categorized into the following subgroups: wingless (WNT), sonic hedgehog (SHH), group 3, and group 4. Each subgroup is characterized by a unique set of genetics and gene expression as well as demographic and clinical features. [from OMIM]

Clinical features

From HPO
Medulloblastoma
MedGen UID:
7517
Concept ID:
C0025149
Neoplastic Process
Medulloblastoma is the most common brain tumor in children. It accounts for 16% of all pediatric brain tumors, and 40% of all cerebellar tumors in childhood are medulloblastoma. Medulloblastoma occurs bimodally, with peak incidences between 3 and 4 years and 8 and 9 years of age. Approximately 10 to 15% of medulloblastomas are diagnosed in infancy. Medulloblastoma accounts for less than 1% of central nervous system (CNS) tumors in adults, with highest incidence in adults 20 to 34 years of age. In 1 to 2% of patients, medulloblastoma is associated with Gorlin syndrome (109400), a nevoid basal carcinoma syndrome. Medulloblastoma also occurs in up to 40% of patients with Turcot syndrome (see 276300). Medulloblastoma is thought to arise from neural stem cell precursors in the granular cell layer of the cerebellum. Standard treatment includes surgery, chemotherapy, and, depending on the age of the patient, radiation therapy (Crawford et al., 2007). Millard and De Braganca (2016) reviewed the histopathologic variants and molecular subgroups of medulloblastoma. Pretreatment prognosis of medulloblastoma has been refined by histopathologic subclassification into the following variants: large-cell medulloblastoma, anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity (MBEN). The latter 2 groups have been shown to have a significantly superior prognosis as compared to the large cell and anaplastic groups in young children. At the molecular level, medulloblastomas have been categorized into the following subgroups: wingless (WNT), sonic hedgehog (SHH), group 3, and group 4. Each subgroup is characterized by a unique set of genetics and gene expression as well as demographic and clinical features.

Conditions with this feature

Gorlin syndrome
MedGen UID:
2554
Concept ID:
C0004779
Neoplastic Process
Nevoid basal cell carcinoma syndrome (NBCCS) is characterized by the development of multiple jaw keratocysts, frequently beginning in the second decade of life, and/or basal cell carcinomas (BCCs) usually from the third decade onward. Approximately 60% of individuals have a recognizable appearance with macrocephaly, frontal bossing, coarse facial features, and facial milia. Most individuals have skeletal anomalies (e.g., bifid ribs, wedge-shaped vertebrae). Ectopic calcification, particularly in the falx, is present in more than 90% of affected individuals by age 20 years. Cardiac and ovarian fibromas occur in approximately 2% and 20% of individuals respectively. Approximately 5% of all children with NBCCS develop medulloblastoma (primitive neuroectodermal tumor), generally the desmoplastic subtype. The risk of developing medulloblastoma is substantially higher in individuals with an SUFU pathogenic variant (33%) than in those with a PTCH1 pathogenic variant (<2%). Peak incidence is at age one to two years. Life expectancy in NBCCS is not significantly different from average.
Medulloblastoma
MedGen UID:
7517
Concept ID:
C0025149
Neoplastic Process
Medulloblastoma is the most common brain tumor in children. It accounts for 16% of all pediatric brain tumors, and 40% of all cerebellar tumors in childhood are medulloblastoma. Medulloblastoma occurs bimodally, with peak incidences between 3 and 4 years and 8 and 9 years of age. Approximately 10 to 15% of medulloblastomas are diagnosed in infancy. Medulloblastoma accounts for less than 1% of central nervous system (CNS) tumors in adults, with highest incidence in adults 20 to 34 years of age. In 1 to 2% of patients, medulloblastoma is associated with Gorlin syndrome (109400), a nevoid basal carcinoma syndrome. Medulloblastoma also occurs in up to 40% of patients with Turcot syndrome (see 276300). Medulloblastoma is thought to arise from neural stem cell precursors in the granular cell layer of the cerebellum. Standard treatment includes surgery, chemotherapy, and, depending on the age of the patient, radiation therapy (Crawford et al., 2007). Millard and De Braganca (2016) reviewed the histopathologic variants and molecular subgroups of medulloblastoma. Pretreatment prognosis of medulloblastoma has been refined by histopathologic subclassification into the following variants: large-cell medulloblastoma, anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity (MBEN). The latter 2 groups have been shown to have a significantly superior prognosis as compared to the large cell and anaplastic groups in young children. At the molecular level, medulloblastomas have been categorized into the following subgroups: wingless (WNT), sonic hedgehog (SHH), group 3, and group 4. Each subgroup is characterized by a unique set of genetics and gene expression as well as demographic and clinical features.
Microcephaly, normal intelligence and immunodeficiency
MedGen UID:
140771
Concept ID:
C0398791
Disease or Syndrome
Nijmegen breakage syndrome (NBS) is characterized by progressive microcephaly, early growth deficiency that improves with age, recurrent respiratory infections, an increased risk for malignancy (primarily lymphoma), and premature ovarian failure in females. Developmental milestones are attained at the usual time during the first year; however, borderline delays in development and hyperactivity may be observed in early childhood. Intellectual abilities tend to decline over time. Recurrent pneumonia and bronchitis may result in respiratory failure and early death. Other reported malignancies include solid tumors (e.g., medulloblastoma, glioma, rhabdomyosarcoma).
Pleuropulmonary blastoma
MedGen UID:
266105
Concept ID:
C1266144
Neoplastic Process
DICER1 tumor predisposition (DICER1) is characterized by an increased risk for pleuropulmonary blastoma (PPB), pulmonary cysts, thyroid gland neoplasia (multinodular goiter, adenomas, and/or thyroid cancer), ovarian tumors (Sertoli-Leydig cell tumor, gynandroblastoma, and sarcoma), and cystic nephroma. Less commonly observed tumors include ciliary body medulloepithelioma, nasal chondromesenchymal hamartoma, embryonal rhabdomyosarcoma, pituitary blastoma, pineoblastoma, central nervous system (CNS) sarcoma, other CNS tumors, and presacral malignant teratoid tumor. The majority of tumors occur in individuals younger than age 40 years. PPB typically presents in infants and children younger than age six years. Ovarian sex cord-stromal tumors are most often diagnosed before age 40 years. Cystic nephroma generally presents in young children but has also been reported in adolescents. Additional clinical features that may be seen include macrocephaly, ocular abnormalities, structural anomalies of the kidney and collecting system, and dental anomalies (bulbous crowns).
Fanconi anemia complementation group N
MedGen UID:
372133
Concept ID:
C1835817
Disease or Syndrome
Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.
Rhabdoid tumor predisposition syndrome 1
MedGen UID:
322892
Concept ID:
C1836327
Disease or Syndrome
The rhabdoid tumor predisposition syndrome is an autosomal dominant cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors (Sevenet et al., 1999). Rhabdoid tumors are a highly malignant group of neoplasms that usually occur in children less than 2 years of age. Malignant rhabdoid tumors (MRTs) of the kidney were first described as a sarcomatous variant of Wilms tumors (Beckwith and Palmer, 1978). Later, extrarenal rhabdoid tumor was reported in numerous locations, including the central nervous system (CNS) (Parham et al., 1994). Classification has been difficult because of considerable variation in the histologic and immunologic characteristics within and between rhabdoid tumors of the liver, soft tissues, and CNS. In the CNS, rhabdoid tumors may be pure rhabdoid tumors or a variant that has been designated atypical teratoid tumor (AT/RT). Genetic Heterogeneity of Rhabdoid Tumor Predisposition Syndrome See also RTPS2 (613325), caused by germline mutation in the SMARCA4 gene (603254) on chromosome 19p13.
Familial adenomatous polyposis 1
MedGen UID:
398651
Concept ID:
C2713442
Disease or Syndrome
APC-associated polyposis conditions include (classic or attenuated) familial adenomatous polyposis (FAP) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). FAP is a colorectal cancer (CRC) predisposition syndrome that can manifest in either classic or attenuated form. Classic FAP is characterized by hundreds to thousands of adenomatous colonic polyps, beginning on average at age 16 years (range 7-36 years). For those with the classic form of FAP, 95% of individuals have polyps by age 35 years; CRC is inevitable without colectomy. The mean age of CRC diagnosis in untreated individuals is 39 years (range 34-43 years). The attenuated form is characterized by multiple colonic polyps (average of 30), more proximally located polyps, and a diagnosis of CRC at a later age than in classic FAP. For those with an attenuated form, there is a 70% lifetime risk of CRC and the mean age of diagnosis is 50-55 years. Extracolonic manifestations are variably present and include polyps of the stomach and duodenum, osteomas, dental abnormalities, congenital hypertrophy of the retinal pigment epithelium (CHRPE), benign cutaneous lesions, desmoid tumors, adrenal masses, and other associated cancers. GAPPS is characterized by proximal gastric polyposis, increased risk of gastric adenocarcinoma, and no duodenal or colonic involvement in most individuals reported.
Glioma susceptibility 3
MedGen UID:
442777
Concept ID:
C2751641
Finding
Any malignant glioma in which the cause of the disease is a mutation in the BRCA2 gene.
Mismatch repair cancer syndrome 1
MedGen UID:
1748029
Concept ID:
C5399763
Disease or Syndrome
Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.
Basal cell nevus syndrome 2
MedGen UID:
1841087
Concept ID:
C5830451
Neoplastic Process
The basal cell nevus syndrome (BCNS), also known as Gorlin syndrome, is characterized by numerous basal cell cancers and epidermal cysts of the skin, calcified dural folds, keratocysts of the jaws, palmar and plantar pits, ovarian fibromas, medulloblastomas, lymphomesenteric cysts, fetal rhabdomyomas, and various stigmata of maldevelopment (e.g., rib and vertebral abnormalities, cleft lip or cleft palate, and cortical defects of bones) (summary by Koch et al., 2002). For a discussion of genetic heterogeneity of BCNS, see BCNS1 (109400).

Professional guidelines

PubMed

Ligon JA, Sayour EJ
Neuro Oncol 2023 Apr 6;25(4):628-630. doi: 10.1093/neuonc/noad005. PMID: 36629263Free PMC Article
Pollack IF, Agnihotri S, Broniscer A
J Neurosurg Pediatr 2019 Mar 1;23(3):261-273. doi: 10.3171/2018.10.PEDS18377. PMID: 30835699Free PMC Article
Paulino AC
Curr Probl Cancer 2002 Nov-Dec;26(6):317-56. doi: 10.1067/mcn.2002.130267. PMID: 12447347

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central Nervous System Cancers, 2023

Recent clinical studies

Etiology

Jackson K, Packer RJ
Curr Neurol Neurosci Rep 2023 Dec;23(12):841-848. Epub 2023 Nov 9 doi: 10.1007/s11910-023-01316-9. PMID: 37943476Free PMC Article
Beccaria K, Padovani L, Bouchoucha Y, Doz F
Curr Opin Oncol 2021 Nov 1;33(6):615-620. doi: 10.1097/CCO.0000000000000788. PMID: 34482338
Bouffet E
Neurochirurgie 2021 Feb;67(1):61-68. Epub 2019 Jun 20 doi: 10.1016/j.neuchi.2019.05.007. PMID: 31229532
Orr BA
Brain Pathol 2020 May;30(3):664-678. doi: 10.1111/bpa.12837. PMID: 32239782Free PMC Article
Quinlan A, Rizzolo D
JAAPA 2017 Oct;30(10):30-36. doi: 10.1097/01.JAA.0000524717.71084.50. PMID: 28953021

Diagnosis

Cotter JA, Hawkins C
Pediatr Dev Pathol 2022 Jan-Feb;25(1):23-33. doi: 10.1177/10935266211018931. PMID: 35168417
Nat Rev Dis Primers 2019 Feb 14;5(1):12. doi: 10.1038/s41572-019-0067-2. PMID: 30765710
Guerreiro Stucklin AS, Grotzer MA
Handb Clin Neurol 2018;155:289-299. doi: 10.1016/B978-0-444-64189-2.00019-6. PMID: 29891066
Quinlan A, Rizzolo D
JAAPA 2017 Oct;30(10):30-36. doi: 10.1097/01.JAA.0000524717.71084.50. PMID: 28953021
Hirsch JF, Hoppe-Hirsch E
Adv Tech Stand Neurosurg 1993;20:165-96. doi: 10.1007/978-3-7091-6912-4_5. PMID: 8397534

Therapy

Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P Jr, Boop FA, Stewart CF, Harreld JH, Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA
Cancer Cell 2021 Nov 8;39(11):1519-1530.e4. Epub 2021 Oct 21 doi: 10.1016/j.ccell.2021.09.012. PMID: 34678152Free PMC Article
Hoerig CM, Plant-Fox AS, Pulley MD, Di K, Bota DA
Pediatr Blood Cancer 2021 Oct;68(10):e29168. Epub 2021 Jun 11 doi: 10.1002/pbc.29168. PMID: 34114315Free PMC Article
Wen J, Hadden MK
Eur J Med Chem 2021 Apr 5;215:113268. Epub 2021 Feb 8 doi: 10.1016/j.ejmech.2021.113268. PMID: 33636537Free PMC Article
Bouffet E
Neurochirurgie 2021 Feb;67(1):61-68. Epub 2019 Jun 20 doi: 10.1016/j.neuchi.2019.05.007. PMID: 31229532
Gajjar A, Kühl J, Epelman S, Bailey C, Allen J
Childs Nerv Syst 1999 Oct;15(10):554-62. doi: 10.1007/s003810050543. PMID: 10550586

Prognosis

Gerber NU, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S
Cancer Treat Rev 2014 Apr;40(3):356-65. Epub 2013 Dec 6 doi: 10.1016/j.ctrv.2013.11.010. PMID: 24389035
Mehta RI, Cutler AR, Lasky JL 3rd, Yong WH, Lerner JT, Hirota BK, Salamon N, Mathern GW, Vinters HV
Hum Pathol 2009 Nov;40(11):1661-5. Epub 2009 Aug 19 doi: 10.1016/j.humpath.2009.04.024. PMID: 19695677
Paulino AC
Oncology (Williston Park) 1997 Jun;11(6):813-23; discussion 823, 827-8, 831. PMID: 9189939
Gökalp HZ, Arasil E, Kanpolat Y, Erdogan A, Deda H, Unlü A
Neurochirurgia (Stuttg) 1993 May;36(3):87-9. doi: 10.1055/s-2008-1053802. PMID: 8321384
Elliott AJ, Simpson EM, Oakhill A, Decock R
Dev Med Child Neurol 1989 Feb;31(1):43-6. doi: 10.1111/j.1469-8749.1989.tb08410.x. PMID: 2920872

Clinical prediction guides

Williamson D, Schwalbe EC, Bailey S, Clifford SC
Neuropathol Appl Neurobiol 2023 Jun;49(3):e12903. doi: 10.1111/nan.12903. PMID: 37021628Free PMC Article
Baroni LV, Muñoz Cassina T, Fernández Ponce N, Pinto N, Vázquez V, Lubieniecki F, Alderete D
J Pediatr Hematol Oncol 2022 Oct 1;44(7):415-418. Epub 2022 Jun 24 doi: 10.1097/MPH.0000000000002448. PMID: 35704799
Archer TC, Mahoney EL, Pomeroy SL
Neurotherapeutics 2017 Apr;14(2):265-273. doi: 10.1007/s13311-017-0526-y. PMID: 28386677Free PMC Article
Byrd T, Grossman RG, Ahmed N
Pediatr Hematol Oncol 2012 Sep;29(6):495-506. Epub 2012 Jun 28 doi: 10.3109/08880018.2012.698372. PMID: 22742590Free PMC Article
Behbahani M, St George EJ, Dunn LT, Hadley DM, Stewart W
Acta Neurochir (Wien) 2011 Jul;153(7):1511-7; discussion 1517. Epub 2011 May 9 doi: 10.1007/s00701-011-1040-3. PMID: 21553317

Recent systematic reviews

Vacek A, Kaliaperumal C
Childs Nerv Syst 2024 Nov;40(11):3527-3536. Epub 2024 Jul 19 doi: 10.1007/s00381-024-06543-0. PMID: 39028348Free PMC Article
Beez T, Munoz-Bendix C, Steiger HJ, Hänggi D
Neurosurg Rev 2021 Feb;44(1):273-278. Epub 2020 Feb 13 doi: 10.1007/s10143-020-01242-1. PMID: 32056026Free PMC Article
Bahmad HF, Poppiti RJ
J Clin Pathol 2020 May;73(5):243-249. Epub 2020 Feb 7 doi: 10.1136/jclinpath-2019-206246. PMID: 32034059
Klumpers MJ, Coenen MJ, Gidding CE, Te Loo DM
Pharmacogenomics 2017 Apr;18(5):501-513. Epub 2017 Mar 27 doi: 10.2217/pgs-2016-0189. PMID: 28346057
Nieder C, Andratschke NH, Grosu AL
Anticancer Res 2016 Oct;36(10):4985-4995. doi: 10.21873/anticanres.11067. PMID: 27798857

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2023
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Central Nervous System Cancers, 2023

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...